The role of interleukin-9 and interleukin-17 in myocarditis with different etiologies

  • 1 Department of Pediatrics, Faculty of Medicine, Sutcu Imam University, Kahramanmaras, Turkey
  • 2 Department of Pediatric, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Sutcu Imam University, Avşar Kampüsü, Kahramanmaras 46100, Turkey
  • 3 Department of Biochemistry, Faculty of Medicine, Sutcu Imam University, Kahramanmaras, Turkey
  • 4 Department of Physiology, Faculty of Medicine, Sutcu Imam University, Kahramanmaras, Turkey
Tuğba Kandemir Gülmez, Can AcipayamORCID iD: https://orcid.org/0000-0002-6379-224X, Metin Kilinç and Nurten Seringeç Akkeçeci

Abstract

Objective

Myocarditis is an inflammatory disease of the cardiac muscle. Prognosis is most often good but, in some patients, the disease can be fulminant. Our aim with this study was to determine interleukin-9 (IL-9) and interleukin-17 (IL-17) levels in myocarditis cases with different etiologies.

Materials and methods

Thirty one patients with myocarditis and 30 healthy controls of similar age and gender without a history of chronic disease were included in the study. All 31 patients were clinically myocarditis. In some of these patients, the cause of myocarditis is acute rheumatic fever or Kawasaki disease. Serum samples of the patients were taken during diagnosis in order to analyze serum IL-9 and IL-17 levels and sedimentation rate, CRP, ASO, pro-BNP, CK-MB, and Troponin-I tests were performed.

Results

It was found that IL-17 levels were statistically significant in all acute rheumatic fever, Myocarditis and Kawasaki patients compared to the control group (p = 0.001) and that cut-off was 4.30 pg/mL. This value was determined to be 71% sensitive and 67% specific for IL-17 (AUC = 0.761).

Conclusions

Both of the mean and median levels of IL-17 were significantly higher in pediatric patients with myocarditis than in healthy children. Our study made us think that complications of myocarditis and associated morbidity can be prevented by IL17 inhibitors. The high levels of IL17 found in our study may be a reference for future study.

  • 1.

    Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation 2006;113:876–90.

    • Crossref
    • PubMed
    • Export Citation
  • 2.

    McCarthy RE 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000;342:690–5.

    • Crossref
    • PubMed
    • Export Citation
  • 3.

    Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young. American Heart Association. Circulation 2004;110:2747–71.

    • Crossref
    • Export Citation
  • 4.

    Mirkinson L. The diagnosis of rheumatic fever. Pediatr Rev 1998;19:310–1.

    • Crossref
    • Export Citation
  • 5.

    Amigo MC, Martínez-Lavín M, Reyes PA. Acute rheumatic fever. Rheum Dis Clin North Am 1993;19:333–50.

    • PubMed
    • Export Citation
  • 6.

    Xavier JL Jr, Matos Soeiro Ad, Lopes AS, Spina GS, Serrano CV Jr, Oliveira MT Jr. Clinically manifested myocarditis in acute rheumatic fever. Arq Bras Cardiol 2014;102:e17–20.

    • PubMed
    • Export Citation
  • 7.

    Wessely R, Henke A, Zell R, Kandolf R, Knowlton KU. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation 1998;98:450–7.

    • Crossref
    • Export Citation
  • 8.

    Rowley AH, Shulman ST. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007;19:71–4.

    • Crossref
    • PubMed
    • Export Citation
  • 9.

    Blank M, Aron-Maor A, Shoenfeld Y. From rheumatic fever to Libman-Sacks endocarditis: is there any possible pathogenetic link? Lupus 2005;14:697–701.

    • Crossref
    • PubMed
    • Export Citation
  • 10.

    Toor D, Sharma N. T cell subsets: an integral component in pathogenesis of rheumatic heart disease. Immunol Res 2018;66:18–30.

    • Crossref
    • PubMed
    • Export Citation
  • 11.

    Korn T, Betteli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485–517.

    • Crossref
    • PubMed
    • Export Citation
  • 12.

    Renauld JC, Kermouni A, Vink A, Louahed J, Van Snick J. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukocyte Biol 1995;57:353–360.

    • Crossref
    • Export Citation
  • 13.

    Knowlton KU, Badorff C. The immune system in viral myocarditis: maintaining the balance. Circ Res 1999;85: 559–61.

    • Crossref
    • PubMed
    • Export Citation
  • 14.

    Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998;188:1307–20.

    • Crossref
    • PubMed
    • Export Citation
  • 15.

    Louahed J, Toda M, Jen J, Hamid Q, Renauld JC, Levitt RC, et al. Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol 2000;22:649–56.

    • Crossref
    • PubMed
    • Export Citation
  • 16.

    Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122–31.

    • Crossref
    • PubMed
    • Export Citation
  • 17.

    Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006;17:699–706.

    • Crossref
    • PubMed
    • Export Citation
  • 18.

    Liuzzo G, Trotta F, Pedicino D. Interleukin17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J 2013;34:556–9.

    • Crossref
    • Export Citation
  • 19.

    Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011;31:1565–72.

    • Crossref
    • PubMed
    • Export Citation
  • 20.

    Zhang S, Yuan J, Yu M, Fan H, Guo ZQ, Yang R, et al. IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome. PLoS One 2012;7:e40641.

    • Crossref
    • PubMed
    • Export Citation
  • 21.

    Fala L. Cosentyx (Secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. Am Health Drug Benefits 2016;9:60–3.

    • PubMed
    • Export Citation
  • 22.

    Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101–4.

    • Crossref
    • PubMed
    • Export Citation
  • 23.

    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461–3.

    • Crossref
    • PubMed
    • Export Citation
  • 24.

    Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001;108:430–8.

    • Crossref
    • PubMed
    • Export Citation
  • 25.

    Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500–8.

    • Crossref
    • PubMed
    • Export Citation
  • 26.

    Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009;4:e5903.

    • Crossref
    • PubMed
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Turkish Journal of Biochemistry (TJB), official journal of Turkish Biochemical Society, is issued electronically every 2 months. The main aim of the journal is to support the research and publishing culture by ensuring that every published manuscript has an added value and thus providing international acceptance of the “readability” of the manuscripts published in the journal.

Search